JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering sustainable bio-based pr ...

Core Insights - Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnostics Limited to support the launch of its recombinant proteins for serum-free cell culture media applications in various markets [1][2][4] Company Overview - Dyadic is a global biotechnology company that produces precision-engineered, animal-free proteins and enzymes for life science, food & nutrition, and bioindustrial markets [1][5] - The company utilizes proprietary microbial expression platforms to manufacture recombinant proteins, which are designed to enable customers to develop more efficient and sustainable products [5] Partnership Details - Under the agreement, Opes will leverage its existing relationships to identify potential customers primarily in Europe, Israel, and Asia, facilitating market entry for Dyadic's recombinant protein portfolio [2][3] - The collaboration aims to enhance the penetration of Dyadic's products in industries such as research, diagnostics, cultured meat, and biomanufacturing [3][4] Market Strategy - The partnership is expected to drive the adoption of Dyadic's cell culture media products into expanding markets, transitioning the company from development activities to broader commercial engagement [4]

PresentationI'd now like to turn the floor over to today's host, Joe Hazelton, President and Chief Operating Officer at Dyadic International. Sir, the floor is yours.Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter Investment Conference 2025. The next presenting company is Dyadic International. [Operator Instructions]Joseph HazeltonPresident & COO Thank you, and good morning, everyone, and thanks for joining us today. I'm Joe Hazelton, President and Chief Operating Officer of Dyadic Applie ...

Summary of Dyadic International Conference Call - December 09, 2025 Company Overview - **Company**: Dyadic International (NasdaqCM:DYAI) - **Industry**: Biomanufacturing, Life Sciences, Food Nutrition, Bio-Industrial Markets - **Focus**: Scalable, animal-free recombinant protein solutions Key Points and Arguments 1. **Commercial Inflection Point**: Dyadic is at a significant commercial inflection point with multiple products entering the market and active revenue engines [2][4][30] 2. **Transition from R&D to Commercialization**: The company has shifted focus from R&D and grant-based revenues to commercial applications, particularly in non-therapeutic areas that do not require FDA review [3][5][30] 3. **Product Launch Timeline**: Dyadic expects multiple product launches starting in 2025 and continuing through 2027, with a focus on life sciences, food nutrition, and bio-industrial segments [4][10][32] 4. **Platform Technologies**: The company utilizes two main platforms, C1 and Dapibus, designed for speed, productivity, scale, and low cost, to produce recombinant animal-free protein solutions [7][9][30] 5. **Market Segments**: - **Life Sciences**: Focus on cell culture media, cell and gene therapy, and high-value proteins like human transferrin and albumin [11][15][19] - **Food Nutrition**: Targeting the alternative protein market, particularly non-animal dairy and functional food proteins, with a market size estimated at $50-$70 billion [12][22] - **Bio-Industrial**: Re-entering the market through partnerships, focusing on cellulosic enzymes with a market size of approximately $6 billion [13][14][23] 6. **Revenue Generation Strategy**: Dyadic employs a three-pillar strategy: buy, brand, and build, allowing for direct sales, licensing, and partnerships to monetize its technology [9][10][19] 7. **Partnerships**: Collaborations with companies like Proliant Health and Fermbox Bio are expected to drive revenue growth and product launches [16][23][29] 8. **Regulatory Advantages**: The focus on non-therapeutic products allows for faster market entry, with timelines of 12-18 months from proof of concept to revenue [5][18][31] 9. **Financial Projections**: The company anticipates meaningful revenue growth starting in early 2026, with a revenue run rate of approximately $12 million needed to reach cash flow positive status [33][37] Additional Important Information - **Innovation and Technology**: Dyadic has access to CRISPR technology, enhancing its ability to optimize production strains [4][30] - **Market Trends**: The shift towards sustainable and predictable proteins is driving demand for Dyadic's products, particularly in the context of growing consumer preference for non-animal sources [3][12] - **Future Outlook**: The company is positioned for significant growth with a layered revenue approach, leveraging existing partnerships and expanding its product portfolio [26][27][32] This summary encapsulates the key insights from the Dyadic International conference call, highlighting the company's strategic direction, market opportunities, and financial outlook.

JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets, and BRIG BIO (official legal entity The Protein Collective B.V.), a Netherlands-based developer of next-generation recombinant dairy ingredients, today announced the signing of a Development and Commercialization Agreement to jointly ...

Financial Data and Key Metrics Changes - Total revenues for Q3 2025 decreased to $1,165,000 from $1,958,000 in the same period a year ago, primarily due to declines in research and development revenue and license and milestone revenue [23][24] - Research and development expenses increased to $572,000 from $460,000 year-over-year, driven by a rise in active internal research initiatives [24] - Net loss for Q3 2025 increased to $1,976,000 or $0.06 per share compared to a loss of $203,000 or $0.01 per share in the same period last year [25] Business Line Data and Key Metrics Changes - The Life Sciences segment is now operating as a product company, manufacturing and supplying lab-grade materials for multiple recombinant proteins [5][6] - The recombinant human albumin program is advancing towards a commercial launch in early 2026, with significant milestone payments received from ProLiant [6][7] - The first bulk purchase order for a Dyadic produced protein was achieved in October, validating the market readiness of the technology [8] Market Data and Key Metrics Changes - The cell culture media market is identified as a dynamic growth area, requiring consistent animal-free proteins for scalability and regulatory confidence [6] - The market for DNase one is approximately $250 million for recombinant products, with a broader market of $1.5 billion for all production methods [32] - The animal-free dairy protein market is expected to exceed $20 billion by 2035, driven by demand for sustainable protein production [13] Company Strategy and Development Direction - The company is transitioning from a platform-centric R&D organization to a commercially focused biotechnology company with a growing portfolio of high-value products [4][5] - Dyadic has rebranded as Dyadic Applied Biosolutions and is enhancing its technology foundation with CRISPR Cas9 gene editing capabilities [4][5] - The strategy includes expanding customer engagement in key global markets, particularly in Asia, Europe, and North America [76] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's transformation and execution, highlighting the first commercial bulk sale as a pivotal moment [4][5] - The focus remains on accelerating product sales across life sciences and molecular biology reagent portfolios, with early commercial traction already underway [76] - The company anticipates growth in product revenue in life sciences and food and nutrition markets while maintaining operating expenses in line with the previous year [26] Other Important Information - The company received a total of $1,500,000 in milestone payments from ProLiant, with expectations to share in profits as albumin products enter the market [7] - Dyadic's collaboration with Intralink aims to accelerate market penetration in Japan and South Korea, leveraging local expertise for effective market reach [11][12] Q&A Session Summary Question: What does the new relationship with ERS Genomics bring to the portfolio? - The CRISPR license enhances the genetic toolbox, accelerating product development and improving optimization yields, providing a competitive advantage in various markets [29][30] Question: How should the DNase one opportunity be viewed for growth in 2026 and beyond? - The DNase one market is substantial, and the focus is on securing OEM agreements for bulk sales, with expectations for steady growth as higher margin segments are targeted [32][34] Question: What characteristics of customers are expected in the Asian markets for DNase one and transferrin? - The target customers include cell and gene therapy manufacturers and suppliers, focusing on bulk purchase orders rather than individual institutions [36][37] Question: Can you elaborate on the CRISPR ERS agreement structure? - The agreement involves improving fungal cell lines for efficiency and quality, with confidentiality around financial specifics, but it is not comparable to CRISPR applications in pharmaceuticals [45][46] Question: How is the infant nutrition product being marketed? - The goal is to mimic human breast milk and bovine milk, with a focus on regulatory hurdles and consumer acceptance, presenting a significant opportunity in the market [51][53]

Exhibit 99.1 Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress ● Completed strategic pivot from R&D focus to commercial focus ● Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations ● Advanced multiple recombinant protein programs toward commercialization ● Achieved key development and commercial milestones across life sciences and nutrition markets ● First purchase order received in cell cultur ...

Financial Performance - Total revenue for Q3 2025 was $1,164,617, a decrease of 40.5% compared to $1,957,500 in Q3 2024[15] - Research and development revenue for Q3 2025 was $350,046, down 34.2% from $532,500 in Q3 2024[15] - Grant revenue increased to $814,571 in Q3 2025, compared to $0 in Q3 2024[15] - Net loss for Q3 2025 was $1,976,012, compared to a net loss of $203,460 in Q3 2024, representing a significant increase in losses[15] - Basic and diluted net loss per common share for Q3 2025 was $0.06, compared to $0.01 in Q3 2024[15] - For the nine months ended September 30, 2025, Dyadic reported a net loss of $5,797,365, compared to a net loss of $4,258,279 for the same period in 2024, indicating an increase in losses of approximately 36.2%[19] - For the nine months ended September 30, 2025, total revenues were $2,524,819, a decrease of 5.7% compared to $2,678,013 for the same period in 2024[156] - The net loss for the nine months ended September 30, 2025, was $5,797,365, compared to a net loss of $4,258,279 for the same period in 2024, representing a 36.2% increase in losses[156] Assets and Liabilities - Total current assets rose to $11,545,262 as of September 30, 2025, up 17.5% from $9,827,668 as of December 31, 2024[14] - Total liabilities increased to $9,065,423 as of September 30, 2025, compared to $7,459,985 as of December 31, 2024, reflecting a 21.5% rise[14] - Total stockholders' equity as of September 30, 2025, was $2,607,334, an increase from $2,470,290 as of December 31, 2024[14] - The accumulated deficit increased to $91,883,845 as of September 30, 2025, from $86,086,480 as of December 31, 2024[14] - As of September 30, 2025, Dyadic's total cash, cash equivalents, and restricted cash amounted to $7,155,788, up from $5,921,614 at the end of the same period in 2024, representing a 20.9% increase[19] - As of September 30, 2025, the company held $10.4 million in cash, cash equivalents, and investment securities, an increase from $9.3 million as of December 31, 2024[155] Research and Development - The company expects to incur losses and negative cash flows as it continues to develop its Dapibus and C1 platforms, indicating ongoing investment in R&D[27] - Research and development costs for the three months ended September 30, 2025, totaled $571,872, an increase of 24.2% from $460,241 in the same period of 2024[76] - For the nine months ended September 30, 2025, research and development costs reached $1,696,230, up 13.2% from $1,498,593 in 2024[76] - Research and development expenses for outside contracted services increased to $1,357,727 for the nine months ended September 30, 2025, compared to $1,119,502 in 2024, reflecting a 21.3% rise[156] - Dyadic is conducting internal and collaborative R&D to advance its microbial platforms across both pharmaceutical and non-pharmaceutical applications[178] Grants and Collaborations - Dyadic received a grant of $3,092,136 from the Gates Foundation for the development of monoclonal antibodies, highlighting its focus on revenue-generating collaborations[34] - The Company received a grant of $3,092,136 from the Gates Foundation for monoclonal antibody development, with approximately $2.4 million received as of September 30, 2025[93][94] - A funding award of $4.5 million was received from CEPI to advance the C1 platform, with the Company set to receive up to $2.4 million as a subcontractor[98] - The Company recognized grant revenue of $287,209 and $462,754, respectively, related to the CEPI Grant for the three and nine months ended September 30, 2025[99] - Dyadic has received a total of approximately $2.4 million in funding from the Gates Foundation for developing low-cost monoclonal antibodies for malaria and RSV[188] Stock and Financing - The company issued 6,052,000 shares of common stock in Q2 2025, raising approximately $4,940,695 after offering costs[17] - The company completed an underwritten offering of 6,052,000 shares at a price of $0.95 per share, raising net proceeds of $4.9 million[37] - The Company issued senior secured convertible promissory notes with an aggregate principal amount of $6.0 million, with interest payable quarterly at a rate of 8% per annum[112][113] - As of September 30, 2025, the accrued interest on the Convertible Notes to related parties was $25,133 and to other third parties was $60,000[122] - The company granted 698,500 stock options during the nine months ended September 30, 2025, with an average exercise price of $1.71[135] Strategic Initiatives - Dyadic's strategic shift focuses on commercializing non-therapeutic proteins, aiming for faster revenue generation and broader market reach[25] - Dyadic expects to commercialize multiple Dapibus™-enabled products starting in 2025 through strategic partnerships and internal manufacturing initiatives[164] - Dyadic partnered with Intralink to expand its commercial efforts in Japan and South Korea, targeting high-value animal-free proteins[184] - Dyadic rebranded as Dyadic Applied BioSolutions and launched a redesigned corporate website to support commercial growth[184] Compliance and Taxation - The company has cured Nasdaq listing deficiencies and regained compliance with the minimum Market Value of Listed Securities and Minimum Bid Price requirements[189] - The Company is required to estimate income taxes in each jurisdiction it operates, considering current tax exposure and temporary differences in revenue and expense recognition[208] - Significant management judgment is necessary for determining the provision for income taxes and deferred tax assets[208] - The Company currently does not face U.S. federal, state, and local tax examinations for years prior to 2022[210] - There are no off-balance sheet arrangements reported by the Company[211]

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced multiple recombinant protein programs toward commercializationAchieved key development and commercial milestones across life sciences and nutrition marketsFirst purchase order received in cell culture media and molecular biology reagent segmentsSecured ERS Genomics CRISPR license to optimize production and produc ...

Core Insights - ERS Genomics and Dyadic Applied BioSolutions have entered into a CRISPR/Cas9 license agreement, allowing Dyadic to utilize ERS' extensive patent portfolio to enhance its bioproduction capabilities [1][2][3] Company Overview - ERS Genomics holds a portfolio of over 100 patents worldwide related to CRISPR/Cas9 technology, covering applications across various cell types and synthetic biology [3][6] - Dyadic Applied BioSolutions specializes in producing precision-engineered, animal-free proteins and enzymes for the life sciences, food and nutrition, and bio-industrial markets [5] Agreement Details - The agreement enables Dyadic to integrate CRISPR-based gene editing into its production platforms, specifically the C1 and Dapibus systems, to improve strain performance and product quality [2][3] - Financial details of the agreement have not been disclosed [4] Strategic Implications - The collaboration is expected to accelerate Dyadic's internal product pipeline and enhance the development of customized production strains for partners [2] - ERS Genomics emphasizes the importance of responsible use of CRISPR technology, aiming to support a wide range of applications in life sciences and bio-industrial sectors [2][3]